( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Dr.Harsh Kumar Baid, Dr.Vanita Kumar, Dr.Neelu Gupta, Dr. DharmChand Kothari*


Adenocarcinoma is the most common malignancy of the prostate and one of the leading causes of death in males. Prostate cancer accounts for 14% of cancer deaths, the second highest in men after lung cancer. Serum PSA, Fine Needle Aspiration cytology (FNAC) and core biopsy integration of these methods into diagnostic triad has enhanced the early detection of prostate cancer at early stage which is curable. Gleason’s grading and serum PSA level are important markers for estimating prognosis of prostatic cancer. Methods and Material: 70 cases of prostatic malignancy, admitted to department of urology were included in this study. Serum PSA level of prostate was record in all cases. Needle Core Biopsy and TURP specimens were examined for histopathological diagnosis and Gleason grading was done according to Gleason grading system where ever possible. Results: In the present study 70 cases of prostatic carcinoma were study out of which 68 cases were adenocarcinoma (63 cases were conventional adenocarcinoma and 5 cases were adenocarcinoma foamy cell variant) and 2 cases were transitional cell carcinoma. Prostatic carcinoma was most common in 7th decade. Maximum No. of patient has serum PSA level >10ng/ml (92.85% cases of carcinoma). The sensitivity (92.3%) were maximum for serum PSA level > 4 ng/ml for prostatic carcinoma. Transitional cell carcinoma (2.9%) is a less common type of carcinoma other than adenocarcinoma which occur primarly in prostate. According to Gleason grading system maximum no. of cases of adenocarcinoma (65.71%) were found moderately differentiated adenocarcinoma which have Gleason score 5-7. Followed by poorly differentiated adenocarcinoma (28.6%) which have Gleason score 8-10. 2 cases were found well differentiated adenocarcinoma (2.9%) which have Gleason score 2-4. Conclusion: Integration of DRE serum PSA level and Biopsy is the best method for detection of Prostate carcinoma. All prostate carcinoma should be graded by Gleason grading system to know the prognosis of carcinoma.

Keywords: Prostate adenocarcinoma, Gleason grading, PSA level, Transitional cell carcinoma.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 March 2024 Issue has been Published, Kindly check it on


    MARCH 2024 issue has been successfully launched on MARCH 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia